Company Description
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States.
Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout.
The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Antoine Awad |
Contact Details
Address: 301 Binney Street, Suite 402 Cambridge, Massachusetts 02142 United States | |
| Phone | 617 401 9975 |
| Website | synlogictx.com |
Stock Details
| Ticker Symbol | SYBX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001527599 |
| CUSIP Number | 87166L100 |
| ISIN Number | US87166L2097 |
| Employer ID | 26-1824804 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Antoine Awad | Principal Executive Officer |
| Dr. Timothy K. Lu M.D., Ph.D. | Co-Founder and Member of Scientific Advisory Board |
| Dr. James J. Collins Ph.D. | Co-Founder and Member of Scientific Advisory Board |
| Mary Beth Dooley | Vice President, Head of Finance and Principal Financial Officer and Principal Accounting Officer |
| Ajay Munshi | Vice President of Corporate Development |
| Dr. Neal Sondheimer M.D., Ph.D. | Vice President and Head of Clinical |
| Dr. Jose-Carlos Gutierrez-Ramos Ph.D. | Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Nov 12, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 6, 2024 | DEF 14A | Other definitive proxy statements |
| Nov 5, 2024 | ARS | Filing |
| Aug 8, 2024 | 8-K | Current Report |
| Aug 8, 2024 | 10-Q | Quarterly Report |
| May 16, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |